HOW WE PROTECT WITH A2M
Arthritis affects nearly 27 million persons yearly in the United States. Arthritis burdens the nation with lost productivity, suffering, lost work days and an increase in medical bills. Current methods of treating arthritis offer temporal relief but have side effects and are ineffective in treating the root cause of arthritis.
The powerful inhibitor Alpha-2-macroglobulin (A2M) stops the progression of arthritis by preventing the breakdown and loss of cartilage. With the aid of breakthrough molecular technology, A2M can be delivered in high concentrations
into the joint space protecting it from the destructive proteins responsible for arthritis. Arthritic joints make several chemicals that destroy the cartilage and these chemicals damage the cells found in the leg, but A2M captures these “bad” chemicals produced in the knee, neutralizing their degenerative effects.
send us a message